$SBPH News
Last published 5y ago
- 5y agoFSTXSBPHF-star Therapeutics Completes Combination with Spring Bank PharmaceuticalsPR NewswireF-star Therapeutics, Inc., (Nasdaq: FSTX, as of November 23, 2020) a clinical-stage immuno-oncology company determined to transform the lives of...
- 5y agoSBPHCORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star TherapeuticsPR NewswirePlease replace the release dated November 19, 2020 with the following corrected version due to revisions to the headline. The corrected release...
- 5y agoSBPHSpring Bank Pharmaceuticals Stockholders Approve Combination with F-star TherapeuticsGlobeNewswireHOPKINTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
- 6y agoSBPHSpring Bank Pharmaceuticals Announces Special Dividend of Contingent Value RightsGlobeNewswireHOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
- 6y agoSBPHSpring Bank Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswireHOPKINTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and...
- 6y agoRSTAKCADCOMSBPHMoore Kuehn Encourages RST, AKCA, DCOM, and SBPH Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
- 6y agoVARPFNXSBPHPRNBMoore Kuehn Encourages SBPH, PFNX, VAR, and PRNB Investors to Contact Law FirmGlobeNewswireNEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
- 6y agoSBPHSpring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and Operational ResultsGlobeNewswireAnnounced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs Continued to advance IV SB 11285 clinical trial to...
- 6y agoSBPHSpring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation ImmunotherapiesGlobeNewswireCombined company will operate as F-star Therapeutics and advance pipeline of multiple clinical-stage immuno-oncology programsCombined company expected to have at least $40 million in cash prior to...
- 6y agoSBPHSpring Bank to Present at the Jefferies Virtual Global Healthcare ConferenceGlobeNewswireHOPKINTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
- 6y agoSBPHSpring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 PandemicGlobeNewswirePursuing collaborations to develop internal compounds for potential treatment of COVID-19Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned dose...
- 6y agoSBPHNew patent application published for: Nucleotide and Oligonucleotide ProdrugsUS Patent Applications (USPTO)( 1 of 1 )
- 6y agoSBPHSpring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid TumorsGlobeNewswireHOPKINTON, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and...
- 6y agoSBPHSpring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial ResultsGlobeNewswireHOPKINTON, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
- 6y agoSBPHSpring Bank Discontinues Development of Inarigivir for the Treatment of HBVGlobeNewswireContinuing to focus on immuno-oncology & inflammation, including IV STING agonist clinical program, oral STING antagonist platform and STING agonist ADCsAdjusting cost structure to fund operations...
- 6y agoSBPHSpring Bank Stops Dosing of Inarigivir Patients in Phase 2 ProgramGlobeNewswireHOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
- 6y agoSBPHSpring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019GlobeNewswireHOPKINTON, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
- 7y agoSBPHSpring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and Operational Results and Provides Corporate UpdateGlobeNewswireHOPKINTON, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
- 7y agoSBPHSpring Bank Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B PatientsGlobeNewswire7 of 30 patients were HBsAg responders with ≥ 0.5log₁₀ reduction Inarigivir 50mg plus Vemlidy® 25mg was generally safe and well tolerated at 12 weeks Evaluation of inarigivir 200mg and 400mg...
- 7y agoSBPHSpring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NYGlobeNewswireHOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
- 7y agoSBPHYale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank’s STING Agonist Development Compound, and Radiation Therapy in Cancer at the 2019 ASTRO Annual MeetingGlobeNewswireHOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
- 8y agoSBPHSpring Bank Pharmaceuticals (SBPH) CEO Martin Driscoll on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoARWRSBPHArrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis BBusiness WirePASADENA, Calif. & HOPKINTON, Mass.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced an agreement to perform collaborative studies on Arrowhead’s ARC-520 and Spring Ban ...